These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30730272)

  • 21. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
    Gajewski TF
    Semin Oncol; 2015 Aug; 42(4):663-71. PubMed ID: 26320069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
    Balta E; Wabnitz GH; Samstag Y
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators.
    Hou J; Wang Y; Shi L; Chen Y; Xu C; Saeedi A; Pan K; Bohat R; Egan NA; McKenzie JA; Mbofung RM; Williams LJ; Yang Z; Sun M; Liang X; Rodon Ahnert J; Varadarajan N; Yee C; Chen Y; Hwu P; Peng W
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor Immunology and Tumor Evolution: Intertwined Histories.
    Galon J; Bruni D
    Immunity; 2020 Jan; 52(1):55-81. PubMed ID: 31940273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.
    Rivadeneira DB; Delgoffe GM
    Clin Cancer Res; 2018 Jun; 24(11):2473-2481. PubMed ID: 29386217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunosuppression in the tumor microenvironment: where are we standing?
    Umansky V
    Semin Cancer Biol; 2012 Aug; 22(4):273-4. PubMed ID: 22709654
    [No Abstract]   [Full Text] [Related]  

  • 27. Migrating into the Tumor: a Roadmap for T Cells.
    van der Woude LL; Gorris MAJ; Halilovic A; Figdor CG; de Vries IJM
    Trends Cancer; 2017 Nov; 3(11):797-808. PubMed ID: 29120755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.
    Hurwitz AA; Watkins SK
    Cancer Immunol Immunother; 2012 Feb; 61(2):289-293. PubMed ID: 22237887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune metabolism in PD-1 blockade-based cancer immunotherapy.
    Kumar A; Chamoto K
    Int Immunol; 2021 Jan; 33(1):17-26. PubMed ID: 32622347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer immunotherapy: moving forward with peptide T cell vaccines.
    Kumai T; Fan A; Harabuchi Y; Celis E
    Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Editorial: international reviews of immunology.
    Internati MC; Mirandola L; Bot A
    Int Rev Immunol; 2014 Oct; 33(5):365-6. PubMed ID: 25277338
    [No Abstract]   [Full Text] [Related]  

  • 32. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
    Kumar A; Chamoto K; Chowdhury PS; Honjo T
    Elife; 2020 Mar; 9():. PubMed ID: 32122466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tackling Resistance to Cancer Immunotherapy: What Do We Know?
    Gondhowiardjo SA; Handoko ; Jayalie VF; Apriantoni R; Barata AR; Senoaji F; Utami IJW; Maubere F; Nuryadi E; Giselvania A
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32911646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In situ antitumor vaccination: Targeting the tumor microenvironment.
    Li H; Yu J; Wu Y; Shao B; Wei X
    J Cell Physiol; 2020 Jul; 235(7-8):5490-5500. PubMed ID: 32030759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy.
    Griffiths JI; Wallet P; Pflieger LT; Stenehjem D; Liu X; Cosgrove PA; Leggett NA; McQuerry JA; Shrestha G; Rossetti M; Sunga G; Moos PJ; Adler FR; Chang JT; Sharma S; Bild AH
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):16072-16082. PubMed ID: 32571915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adoptive T-cell therapy: a need for standard immune monitoring.
    Klaver Y; Kunert A; Sleijfer S; Debets R; Lamers CH
    Immunotherapy; 2015; 7(5):513-33. PubMed ID: 26065477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibroblasts Fuel Immune Escape in the Tumor Microenvironment.
    De Jaeghere EA; Denys HG; De Wever O
    Trends Cancer; 2019 Nov; 5(11):704-723. PubMed ID: 31735289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges and future perspectives of T cell immunotherapy in cancer.
    de Aquino MT; Malhotra A; Mishra MK; Shanker A
    Immunol Lett; 2015 Aug; 166(2):117-33. PubMed ID: 26096822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy.
    Hardaway JC; Prince E; Arepally A; Katz SC
    J Vasc Interv Radiol; 2018 Jul; 29(7):1017-1021.e1. PubMed ID: 29935783
    [No Abstract]   [Full Text] [Related]  

  • 40. How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.
    Li J; Stanger BZ
    Cancer Res; 2020 Oct; 80(19):4037-4041. PubMed ID: 32554552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.